Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IC351: Completed Phase II trial enrollment

Icos Corp. (ICOS), Bothell, Wash.
Product: IC351
Business: Reproductive
Therapeutic

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE